CJC-1295 with DAC vs No DAC — Key Structural Differences

A 2010 study published in the Journal of Clinical Endocrinology and Metabolism found that CJC-1295 with DAC produced sustained growth hormone (GH) elevation for 6–13 days following a single subcutaneous injection. A duration that modified GRF 1-29 (CJC-1295 without DAC) cannot achieve. The difference comes down to a single structural modification: the Drug Affinity Complex (DAC) is a synthetic linker molecule attached to the peptide backbone that binds to serum albumin, dramatically extending plasma half-life from approximately 30 minutes to over 8 days. That's not a minor adjustment. It changes how the compound is dosed, how it affects endogenous GH pulsatility, and what applications it's best suited for.

We've worked with research institutions comparing both forms across physiological models. The version you select depends entirely on whether your protocol prioritizes sustained baseline GH elevation or preservation of natural pulsatile secretion patterns.

Is CJC-1295 with DAC the same as CJC-1295 without DAC?

No. CJC-1295 with DAC and CJC-1295 without DAC (modified GRF 1-29) are structurally and pharmacokinetically distinct peptides. The DAC modification extends half-life from 30 minutes to over 8 days, enabling sustained GH release for up to two weeks from a single dose, while the non-DAC version mimics natural pulsatile GH secretion with a peak at 30 minutes post-injection. The structural difference determines dosing frequency, plasma kinetics, and research applications.

The confusion stems from nomenclature overlap. Both peptides derive from the same base sequence (growth hormone-releasing hormone analogue, amino acids 1-29), but only one carries the DAC linker. Researchers often shorten 'CJC-1295 without DAC' to 'CJC-1295' in casual reference, creating the false impression they're identical compounds. They're not. This article covers the exact structural modification that separates them, how DAC binding to albumin alters plasma kinetics, what dosing protocols each version requires, and which peptide fits protocols prioritizing pulsatile versus sustained GH elevation.

What the DAC Modification Actually Does to Peptide Structure

The Drug Affinity Complex (DAC) is a reactive chemical group. Specifically, maleimidopropionic acid. Covalently bonded to the lysine residue at position 15 of the CJC-1295 peptide backbone. Once injected subcutaneously, this DAC linker binds non-covalently to circulating serum albumin, the most abundant plasma protein in human blood. Albumin has a half-life of approximately 19 days, and any molecule bound to it effectively 'hitchhikes' through circulation at albumin's clearance rate rather than its own. For CJC-1295 without DAC (modified GRF 1-29), enzymatic degradation by dipeptidyl peptidase-4 (DPP-IV) begins within minutes of injection, resulting in a plasma half-life of roughly 30 minutes. The DAC modification blocks this degradation pathway by sterically shielding the peptide from DPP-IV while tethered to albumin.

The result: CJC-1295 with DAC achieves a plasma half-life exceeding 8 days. A single 60 mcg/kg subcutaneous dose produces measurable GH elevation for 6–13 days, as demonstrated in the Phase 1 trial conducted at McGill University and published in JCEM. Modified GRF 1-29 (no DAC), by contrast, reaches peak GH levels 30 minutes post-injection and returns to baseline within 2–3 hours. Both peptides bind to the same growth hormone-releasing hormone (GHRH) receptor on anterior pituitary somatotrophs, but the kinetics of receptor engagement differ entirely. One delivers a sharp pulsatile spike; the other sustains receptor activation across multiple endogenous GH pulses.

Our team has found that research protocols requiring daily or twice-daily dosing typically favor modified GRF 1-29 because it preserves natural ultradian GH rhythm. Protocols aiming for sustained baseline GH elevation without daily administration use CJC-1295 with DAC instead.

Pharmacokinetic Differences Between CJC-1295 with DAC and Modified GRF 1-29

When you inject CJC-1295 with DAC subcutaneously, plasma GH concentration begins rising within 2–4 hours, peaks around 24–48 hours, and remains elevated above baseline for up to 13 days depending on dose. The area under the curve (AUC) for GH exposure is approximately 10–15 times greater than what modified GRF 1-29 delivers from a single dose, because the DAC-bound peptide continuously stimulates GHRH receptors as it slowly dissociates from albumin over days. This produces a 'tonic' elevation. Baseline GH levels shift upward, but the natural pulsatile architecture (nocturnal GH surge, exercise-induced pulses) is blunted because the pituitary is under continuous GHRH stimulation rather than intermittent signaling.

Modified GRF 1-29 (CJC-1295 without DAC) follows a completely different pattern. Plasma concentration peaks at 15–30 minutes post-injection, triggering a sharp GH pulse lasting 90–120 minutes before returning to baseline. This mirrors endogenous GHRH secretion from the arcuate nucleus. Brief, high-amplitude pulses separated by troughs. Because the peptide is cleared rapidly, repeated dosing (typically 1–3 times daily) is required to sustain GH-elevating effects across a 24-hour period. The trade-off: pulsatile dosing preserves receptor sensitivity and prevents the desensitization that can occur with continuous GHRH receptor activation.

Clinical data from the ConjuChem Phase 2 trial showed that CJC-1295 with DAC dosed once weekly maintained IGF-1 (insulin-like growth factor 1) levels 1.5–2.5 times baseline throughout the dosing interval. Modified GRF 1-29 requires daily dosing to achieve comparable IGF-1 elevation, but IGF-1 fluctuates more. Rising sharply post-dose and declining between doses. Neither approach is 'better'. The choice depends on whether the research model benefits more from stable baseline elevation or preservation of endogenous pulse dynamics.

Dosing Protocols and Reconstitution Standards for Each Peptide Form

CJC-1295 with DAC is typically dosed at 1–2 mg per week in research settings, administered as a single subcutaneous injection. Because plasma half-life exceeds 8 days, there's no pharmacokinetic rationale for more frequent dosing. The peptide remains bioavailable throughout the interval. Most lyophilized CJC-1295 with DAC vials are supplied at 2 mg per vial and reconstituted with 2 mL bacteriostatic water (0.9% benzyl alcohol), yielding a 1 mg/mL solution. Standard weekly dose of 1 mg corresponds to 1 mL of reconstituted solution. Once reconstituted, the peptide must be refrigerated at 2–8°C and used within 28 days. Bacterial growth in bacteriostatic water solutions begins after 30 days even under refrigeration.

Modified GRF 1-29 (CJC-1295 without DAC) is dosed at 100–200 mcg per injection, administered 1–3 times daily depending on protocol goals. The most common research schedule is twice daily: once upon waking (to amplify the morning GH pulse) and once before bed (to enhance nocturnal GH secretion). A typical 2 mg vial reconstituted with 2 mL bacteriostatic water yields a 1 mg/mL (1000 mcg/mL) solution. A 100 mcg dose corresponds to 0.1 mL. Because this peptide is dosed more frequently, researchers often use insulin syringes (0.5 mL or 1 mL capacity) with 0.01 mL graduation marks for precise measurement.

Our experience shows the most common reconstitution error is injecting air into the vial while drawing the solution. The resulting positive pressure forces peptide solution back through the needle during storage, increasing contamination risk and degrading the remaining peptide. Proper technique: inject air equal to the volume you plan to withdraw, invert the vial, draw solution slowly, then remove the syringe without injecting additional air. Store all reconstituted peptides upright in the refrigerator, never frozen. Freezing denatures the tertiary protein structure irreversibly.

CJC-1295 with DAC vs No DAC: Research Application Comparison

What If: CJC-1295 with DAC Scenarios

What If I Accidentally Dose CJC-1295 with DAC Twice in One Week?

Skip the next scheduled dose and resume weekly dosing the following week. Because CJC-1295 with DAC has an 8+ day half-life, overlapping doses compound plasma concentration rather than replacing it. Doubling within 7 days can produce GH levels 2–3× higher than intended, increasing the risk of side effects like joint pain, edema, or insulin resistance. There's no pharmacological 'reversal' for excess peptide already bound to albumin. You must wait for natural clearance. Monitor for signs of GH excess (carpal tunnel-like symptoms, fluid retention, fasting glucose elevation) and consult the supervising researcher if symptoms develop.

What If I Want to Switch from CJC-1295 with DAC to Modified GRF 1-29 Mid-Protocol?

Allow a 14-day washout period before starting modified GRF 1-29 to ensure CJC-1295 with DAC has cleared below detectable plasma levels. Starting pulsatile dosing while DAC-bound peptide is still active creates overlapping GHRH receptor stimulation. The tonic background elevation from residual CJC-1295 with DAC blunts the pulsatile GH response to modified GRF 1-29, defeating the purpose of switching. The washout interval accounts for 1.5 half-lives (8 days × 1.5 = 12 days, rounded to 14 for margin). IGF-1 levels will decline during washout but stabilize once modified GRF 1-29 dosing begins.

What If Modified GRF 1-29 Doesn't Produce a Noticeable GH Pulse in My Research Model?

Verify peptide storage and reconstitution first. Modified GRF 1-29 degrades rapidly if stored above 8°C or exposed to light. If storage conditions were correct, the issue is likely timing or co-administration. Modified GRF 1-29 works synergistically with ghrelin mimetics (GHRP-2, GHRP-6, ipamorelin, hexarelin) because GHRH and ghrelin act on different receptors with amplifying effects. A dose of 100 mcg modified GRF 1-29 alone produces a GH pulse of approximately 2–4× baseline, but the same dose combined with 100 mcg GHRP-6 can produce 8–10× baseline due to receptor synergy. Research models often dose the two peptides together to maximize GH response.

The Direct Truth About CJC-1295 Nomenclature Confusion

Here's the honest answer: the peptide research community created this confusion by inconsistently labeling products. CJC-1295 was originally developed by ConjuChem Biotechnologies with the DAC modification as its defining feature. The clinical trials, the published pharmacokinetic data, and the original patent all refer to the DAC-bound version. Modified GRF 1-29 (the non-DAC version) was developed later as a shorter-acting alternative. Suppliers began calling modified GRF 1-29 'CJC-1295 without DAC' to leverage brand recognition, and now both names circulate interchangeably depending on the vendor. Some researchers use 'CJC-1295' to mean the DAC version and specify 'modified GRF 1-29' for the non-DAC form; others do the opposite.

The practical consequence: you cannot assume a product labeled 'CJC-1295' contains the DAC linker unless the supplier explicitly states it. At Real Peptides, every peptide listing specifies whether DAC is present and provides the exact amino acid sequence with any modifications. We've seen research protocols compromised because investigators assumed 'CJC-1295' meant one form when the supplier shipped the other. The solution is simple. Verify the structural specification with the supplier before ordering. Ask for the molecular weight, the sequence, and whether DAC or any other modification is present. If the supplier can't answer, order elsewhere.

When to Select CJC-1295 with DAC vs Modified GRF 1-29 for Research Protocols

CJC-1295 with DAC suits protocols where sustained baseline GH elevation is the goal and daily dosing isn't feasible. Examples: long-duration metabolic studies tracking IGF-1 over weeks, models examining GH's role in tissue repair or lipolysis where stable exposure matters more than peak amplitude, or any scenario where injection frequency is a limiting factor. The trade-off is loss of pulsatile control. You can't 'turn off' CJC-1295 with DAC once it's bound to albumin. If the research model requires GH elevation only during specific windows (exercise, fasting, sleep), this peptide isn't the right tool.

Modified GRF 1-29 (CJC-1295 without DAC) fits protocols requiring precise timing and preservation of natural GH dynamics. Examples: studies examining GH's role in exercise recovery (dose post-workout to amplify the endogenous GH pulse), sleep architecture research (dose before bed to enhance nocturnal secretion without affecting daytime levels), or any model where receptor desensitization from continuous stimulation would confound results. The cost is dosing frequency. Achieving sustained GH elevation across 24 hours requires 2–3 daily injections. Most research teams find this acceptable given the control it provides.

Our team's position: modified GRF 1-29 is the more versatile peptide for hypothesis-driven research because it allows investigators to isolate specific GH pulses and observe downstream effects without the confounding variable of tonic background elevation. CJC-1295 with DAC works well when the research question concerns chronic GH exposure rather than acute pulsatile signaling. Neither peptide 'replaces' the other. They address different experimental needs. You can explore both forms and see how precise amino-acid sequencing and structural modifications determine research outcomes across our full peptide collection.

The version you select depends entirely on your protocol's hypothesis and dosing constraints. If daily injections fit your model and pulsatile control matters, modified GRF 1-29 delivers more experimental precision. If weekly dosing and stable baseline GH are the priority, CJC-1295 with DAC fits better. Both require rigorous storage discipline. One temperature excursion above 8°C during reconstituted storage can denature the peptide entirely, turning an effective research tool into an expensive saline injection.

All compounds discussed on this page are sold for research use only and are not for human consumption.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

1. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
2. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
3. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
4. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
5. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
6. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
7. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286